Chase Pharmaceuticals Corporation (CPC) is an early stage, product-based, specialty pharmaceutical company focused on the development of novel medications that could revolutionize the treatment of Alzheimer’s disease (AD), one of the greatest unmet needs in clinical neurology.

The objective of our development is to improve the lives of Alzheimer’s patients and their caregivers. The criteria for improvement are:

  • Greater effect on cognition;
  • Lower risk of gastrointestinal and other side effects;
  • Once per day dosing, faster initial titration, fewer or less burdensome monitoring requirements.

The key benefits of the Chase approach to the treatment of AD is the use of proven, currently marketed pharmaceuticals that have been used safely by AD patients and inventing and patenting a way to reposition them in a unique combination that improves, most importantly, the efficacy, but also maintains the current safety profile compared to currently approved medications. The achievement of a significant efficacy benefit is the primary objective.

CPC is well positioned to succeed based on its inventive process and the use of proven drug candidates. Our drug selection and clinical development capabilities, combined with a business model that maximizes use of capital, accent our unique capabilities. Chase Pharmaceuticals thus provides new hope for those now suffering from Alzheimer's disease and related neurodegenerative disorders.